



## Anatara Investor Presentation

MELBOURNE, 8 September 2020: Anatara Lifesciences (ASX: ANR) is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr. Steven Lydeamore, will present today at the ASX Small Mid-Cap Conference 2020, a virtual conference.

A copy of the presentation is attached.

**For more information please contact:**

General inquiries	
Steven Lydeamore CEO, Anatara Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anatara.com	Sue MacLeman Chair, Anatara Lifesciences Ltd +61 (0) 437 211 200 smacleman@anatara.com

### About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

#### Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.


Anatara Lifesciences Limited  
Registered Office

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

Administration and R&D

343 Royal Parade, Parkville, Melbourne, VIC 3052, Australia

Email [info@anatara.com](mailto:info@anatara.com) | Website [anataralifesciences.com](http://anataralifesciences.com)





**ANATARA**  
LIFESCIENCES



ASX Small and Mid-Cap  
Conference

8 SEPTEMBER 2020

-----  
ASX: ANR

**Advancing gastrointestinal health**

# Disclaimer

*The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anantara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.*

*Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.*

*Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.*

*Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.*

*Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.*

# Key Investor Message

More than ever, the world is looking for safe and effective solutions to gut health.

**The Anatará team is focussed on delivering evidence-based, commercially attractive solutions for gastrointestinal diseases in animals and humans.**



# Corporate Fast Facts



ASX ticker code

**ANR**

Share Price

**\$0.19\***

Market Capitalisation

**\$9.5 million\***

Ordinary Shares

**49,856,177**

Options

**2,158,500**

## Board of Directors:

Sue MacLeman

Dr Jane Ryan

Dr Tracie Ramsdale

Dr David Brookes

## Management:

Steve Lydeamore, CEO

Dr Michael West, COO

## Product Development

## Advisory Board:

Prof Peter Gibson

Dr Rebecca Burgell

Dr Jakob Begun

Laureate Prof Nick Talley

Prof Jane Andrews

Prof Barry Campbell

Assoc Prof Simon Keely

Dr Tracey Brown

# Investment highlights

## Human health asset, GaRP:

- Aimed at restoring and maintaining **gut health** with excellent (pre-clinical *in vitro* and *in vivo* animal studies) data
- **Human clinical study** initiation anticipated late 2020
- View to a **partnering deal** by end 2020

## Animal health assets:

- Detach<sup>®</sup> developed for control of scour in piglets
- Livestock market which is in urgent need of non-antibiotic solutions
- New bromelain-based formulations for piglets (in-feed) and poultry ready for challenge trials
- Challenge trials to be undertaken in poultry and piglets (in-feed) to address barriers to partnering

# Irritable Bowel Syndrome



ANATARA  
LIFESCIENCES



# About Irritable Bowel Syndrome (IBS)

- IBS is a functional disorder. Incomplete knowledge of pathology, therefore the approach is symptom management
- Symptoms include abdominal pain, bloating and alternating constipation and diarrhoea
- Patients have a poor quality of life and utilise the healthcare system more than other patients

Region	Prevalence proportion; overall	Prevalence proportion; males	Prevalence proportion; females
World	11.20%	10.47%	16.48%
Africa	11.20%	10.47%	16.48%
Asia	7.80%	7.29%	11.47%
Europe	13.01%	12.17%	19.14%
Latin America and the Caribbean	21.00%	19.64%	30.89%
Northern America	11.80%	11.03%	17.36%
Oceania	15.00%	14.02%	22.06%

Source: Datamonitor Healthcare, Barbezat et. Al., 2002; Lovell and Ford, 2012; Sperber et.al., 2017; United Nations, 2017<sup>1</sup>

**IBS is the most commonly diagnosed gastrointestinal condition and a significant cost burden on health care <sup>2</sup>**



# Global consumer health market opportunity

**US \$8 billion**

**Gastrointestinal supplements and OTC digestive remedies in USA alone <sup>3,4</sup>**

## Probiotic supplements



Align® (P&G) sales  
(U.S.) 2018:  
**US\$171.9m<sup>9</sup>**

## Other GI supplements



Iberogast® (Bayer) sales  
(Germany) 2018:  
**US\$145m<sup>9</sup>**


## OTC digestive supplements



Buscopan® (Sanofi) sales  
(Global) 2018:  
**US\$220m<sup>10</sup>**

(OTC only, excludes prescription sales)

# Compelling Investment Case



3. Mintel's 2018 Digestive Health U.S. – July, 16; 4. Nutrition Business Journal (NBJ); 5. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712-721; 6. Saunjoon L. Yoon, Oliver Grundmann, Keore F. Smith & Sidney R. Mason (2018): Dietary Supplement and Complementary and Alternative Medicine Use Are Highly Prevalent in Patients with Gastrointestinal Disorders: Results from an Online Survey, Journal of Dietary Supplements; 7. O. Grundmann et al. Complementary Therapies in Medicine 41 (2018) 225–230; 8. Grundmann O, Yoon SL. Complementary and alternative medicines in irritable bowel syndrome: An integrative view. World J Gastroenterol 2014; 20(2): 346-362


# GaRP

built on strong scientific foundations

---



# Anatara's Unique Dietary Supplement - How does it work?



Small Intestine

Colon

Correcting gut microbiota to restore normal microbial function

+

Reduction of inflammation

+

Repair of gut lining and barrier defects

=

Alleviation of the symptomatic diarrhoea associated with IBS/IBD.

✓ Bromelain

✓ Other GRAS<sup>11</sup> components

# GaRP has been shown to.....

- **Address the dysbiosis of the microbiome**
  - Inhibiting the attachment and invasion of pro-inflammatory bacteria by **>95%**
- **Reduce gut inflammation**
  - Reducing the production of pro-inflammatory proteins by **>85%**
  - Reducing colon inflammation and disrupted bowel habits by **2.5-fold** in mice
  - Potential to reduce immunosuppressive dosing in IBD when GaRP used as an adjunct to prescription immunosuppressants
- **Promote mucosal healing**
  - Upregulating the expression of mucin genes (MUC2 & MUC6) that are normally downregulated in both IBD and IBS
  - Increasing the expression of mucin genes by a factor of **5 to 7-fold** (MUC2 and MUC6 genes)

# Anticipated Company Milestones

	2018 H1	2018 H2	2019 H1	2019 H2	2020 H1	2020 H2	2021 H1	2021 H2
GaRP commercial feasibility	✓							
Patent Application filed		✓						
In vitro GaRP proof of concept - anti-inflammation - anti-attachment			✓ ✓					
In vitro GaRP proof of concept - mucosal healing				✓				
GaRP animal study (IBD)				✓				
Human clinical study (IBS) - Pre-trial activities - Commencement				✓		★		
Partnering discussions - GaRP partnering deal						★		
Livestock challenge trials - Poultry - Piglets (in-feed)						S	F	S F



ANATARA  
LIFESCIENCES



## Contact Anatara Lifesciences Ltd

Steven Lydeamore, Chief Executive Officer

+61 438 027 172

[slydeamore@anatara.com](mailto:slydeamore@anatara.com)

[www.anataralifesciences.com](http://www.anataralifesciences.com)

@AnataraANR



anatara-lifesciences-ltd 